From Diagnostics to Theranostics – Can Effective Interdisciplinary Communication Save Lives?
Thursday May 16th, 2024 at 2pm ET
Speakers
Mark Bosch MD, FRCPC
Saskatoon, Saskatchewan
Bone Marrow Transplant Hematologist, CAR T Clinical Lead
Associate Professor, Division of Oncology, University of Saskatchewan
Dr. Mark Bosch is a stem cell transplant physician at the Saskatoon Cancer Centre. He completed his medical school and internal medicine at the University of Saskatchewan. He completed this sub-specialty in Hematology and Bone Marrow Transplant at the University of Calgary. Dr. Bosch is very active in administration, teaching, and clinical research in leukemia, lymphoma, CAR T and Bone Marrow transplantation.
John DeCoteau MD, FRCPC
Saskatoon, Saskatchewan
Professor Pathology and Laboratory Medicine, University of Saskatchewan
Associate Member Saskatchewan Cancer Agency
Co-Leader – Translational Cancer Research (TCR) Cluster
Medical Director – Advanced Diagnostic Research Laboratory (ADRL)
Dr. John DeCoteau is a Professor of Pathology and Laboratory Medicine at the University of Saskatchewan where he practices molecular cancer pathology. He received his MD at the University of Saskatchewan and specialty certification in Hematopathology at the University of Toronto. Following that, he pursued post-doctoral research studies related to molecular cancer pathology at Harvard, MIT, and the University of Toronto. He is the Medical Director of the Advanced Diagnostics Research Laboratory (ADRL), an accredited cancer diagnostic and monitoring lab that serves as the Saskatchewan Provincial reference centre for somatic cancer diagnostics, issuing over 4,200 diagnostic reports annually.
Diana N. Ionescu MD, FRCP(C), FCAP
Vancouver, British Columbia
Consultant Pathologist, BC Cancer Agency (BCCA)
Medical Lead, Anatomical Pathology, BCCA
Medical Director Cervical Cancer Screening Laboratory
Medical Director Clinical Trials, BCCA Laboratories
Clinical Professor of Pathology, University of British Columbia
Dr. Ionescu is a graduate of the University of Medicine and Pharmacy “Iuliu Hatieganu” in Cluj Napoca, Romania (1995). Dr. Ionescu completed her Anatomical and Clinical Pathology training at the University of Pittsburgh Medical Center and a Fellowship in Gynecological Pathology at Vancouver General Hospital. Before her residency training, Dr. Ionescu did a Postdoctoral Fellowship in pulmonary research with Dr. J. Hogg at the iCAPTURE Center in Vancouver. She is the recipient of several awards from the Pulmonary Pathology Society and the recipient of Donald King Fellowship from the Armed Forced Institute of Pathology.
Dr. Ionescu is a Consultant Pathologist, Medical Lead of Anatomical Pathology, and Medical Director for Clinical Trials at BC Cancer Laboratory in Vancouver with clinical expertise in lung, breast and gynecological cancers. She also serves as the Medical Director of BC Cervical Cancer Screening Laboratories. Dr. Ionescu is a Clinical Professor of Pathology who served 8 years as the residency program director for the UBC Anatomical Pathology Residency Program, mentoring over 30 residents and fellows, and received the 2022 UBC Mentoring Award.
Her investigational interests include oncologic molecular pathology and biomarker testing, lung cancer pathology, economics of biomarkers, and adult health education. She is the author of over 70 articles and book chapters, is an invited speaker at numerous multidisciplinary national and international conferences, the founder and course director for the Canadian Anatomic and Molecular Pathology (CAMP) and CAMP pathology Oncology Digital Series (CAMP-PODS) and moderator, presenter, and community excellence awardee at ROMPOST TV on Omni TV Canada.
Barbara Melosky MD, FRCPC
Vancouver, British Columbia
Medical Oncologist, BC Cancer
Professor of Medicine, UBC
Dr. Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. She graduated from medical school at the University of Manitoba and did a residency in internal medicine and an oncology fellowship at the University of British Columbia. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group.
Her main focus of clinical trials is on EGFR inhibitors; she is published in this area and is considered a national and international expert. Dr. Melosky has chaired the Canadian Lung Cancer Conference for the last 12 years, which is attended by over 350 participants. She chairs and organized the multi-disciplinary Lung Cancer Journal Club three times yearly. She is chair and created the British Columbia Lung Cancer Biobank.
She is also the chairperson of the Colorectal Screening Program of British Columbia and has a special interest in EGFR receptors and management of side effects.
Learning Objectives
After this episode, the participant will be able to:
- Distinguish between Molecular Tumour Boards and ‘Usual’ Tumour Boards.
- Describe at least one successful team-based approach for bringing on a new biomarker assay.
- Summarize an Oncologist’s perspective on step-wise vs complete reporting for ancillary testing results.